Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The underlying cellular mechanisms leading to frontal cortical hypofunction (i.e., hypofrontality) in schizophrenia remain unclear. Both hypoactive and hyperreactive prefrontal cortical (PFC) states have been reported in schizophrenia patients. Recent proton magnetic resonance spectroscopy studies revealed that antipsychotic-naïve patients with first-psychotic episode exhibit a hyperactive PFC. Conversely, PFC activity seems to be diminished in patients chronically exposed to conventional antipsychotic treatments, an effect that could reflect the therapeutic action as well as some of the impairing side effects induced by long-term blockade of dopamine transmission. In this review, we will provide an evolving picture of the pathophysiology of schizophrenia moving from dopamine to a more glutamatergic-centered hypothesis. We will discuss how alternative antipsychotic strategies may emerge by using drugs that reduce excessive glutamatergic response without altering the balance of synaptic and extrasynaptic normal glutamatergic neurotransmission. Preclinical studies indicate that acamprosate, a FDA approved drug for relapse prevention in detoxified alcoholic patients, reduces the glutamatergic hyperactivity triggered by ethanol withdrawal without depressing normal glutamatergic transmission. Whether this effect is mediated by a direct modulation of NMDA receptors or by antagonism of metabotropic glutamate receptor remains to be determined. We hypothesize that drugs with similar pharmacological actions to acamprosate may provide a better and safer approach to reverse psychotic symptoms and cognitive deficits without altering the balance of excitation and inhibition of the corticolimbic dopamine-PFC system. It is predicted that schizophrenia patients treated with acamprosate-like compounds will not exhibit progressive cortical atrophy associated with the anti-dopaminergic effect of classical antipsychotic exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Dynamic mapping of human cortical development during childhood through early adulthood
Gogtay, N., Giedd, J. N., Lusk, L., Hayashi, K. M., Greenstein, D., Vaituzis, A. C., Nugent, T. F., Herman, D. H., Clasen, L. S., Toga, A. W., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402680101 · Cited by 5,604 · cited 1×
“…1989, Zecevic and Rakic, 1991), while the myelination of axons projecting from the PFC is particularly intense during adolescence and young adulthood (Giedd et al., 1999, Gogtay et al., 2004, Jernigan et al., 1991, Paus et al., 1999, Sowell et al., 2003, Sowell et al., 1999, Toga et al., 2006).”
BackgroundBrain development during childhood and adolescence: a longitudinal MRI study
Giedd, J. N., Blumenthal, J., Jeffries, N. O., Castellanos, F. X., Liu, H., Zijdenbos, A., Paus, T., Evans, A. C., & Rapoport, J. L. (1999) · Nature Neuroscience · doi:10.1038/13158 · Cited by 5,552
Dementia Praecox or the Group of Schizophrenias
(1951) · Journal of the American Medical Association · doi:10.1001/jama.1951.02920270079043 · Cited by 4,407
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535 · cited 2×
“Since these events are probably dependent on plastic changes affecting the glutamatergic (Monyer et al., 1994, Williams et al., 1993) and the DA systems (Leslie et al., 1991, Tarazi et al., 1999), it is not surprising that PFC pyramidal neuron response to DA acquire a mature profile Eur…”
BackgroundResultKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999 · cited 1×
“In fact, cognitive deficits are better predictor of the degree of social disability in patients with schizophrenia than the residual psychotic symptoms (Gold et al., 2002, Green et al., 2000, Green et al., 2002, Hyman and Fenton, 2003, Milev et al., 2005, Rosenheck et al., 2006).”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Synaptic density in human frontal cortex —Developmental changes and effects of aging
Peter R., H. (1979) · Brain Research · doi:10.1016/0006-8993(79)90349-4 · Cited by 2,645 · cited 1×
“Accelerated pruning of redundant connections in the PFC occurs during this developmental stage (Bourgeois et al., 1994, Huttenlocher, 1979, Huttenlocher and Dabholkar, 1997, Zecevic et al., 1989, Zecevic and Rakic, 1991), while the myelination of axons projecting from the PFC is particularly…”
BackgroundMapping cortical change across the human life span
Sowell, E. R., Peterson, B. S., Thompson, P. M., Welcome, S. E., Henkenius, A. L., & Toga, A. W. (2003) · Nature Neuroscience · doi:10.1038/nn1008 · Cited by 2,328 · cited 1×
“…1989, Zecevic and Rakic, 1991), while the myelination of axons projecting from the PFC is particularly intense during adolescence and young adulthood (Giedd et al., 1999, Gogtay et al., 2004, Jernigan et al., 1991, Paus et al., 1999, Sowell et al., 2003, Sowell et al., 1999, Toga et al., 2006).”
BackgroundCortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297 · cited 2×
“, 2006b, Tseng and O'Donnell, 2004, Tseng and O'Donnell, 2007a, Tseng and O'Donnell, 2007b) and functional disruption of this selective neuronal population could ultimately lead to the altered cognitive performances observed in schizophrenia (Lewis et al., 2005).”
BackgroundDopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220 · cited 1×
“Although it is well established that first and second generation antipsychotic drugs exert anti-DA effects, mainly by targeting D2 over D1 receptors (Creese et al., 1976, Seeman and Lee, 1975), prolonged blockade of D2 receptors can also lead to decreased expression of PFC D1 receptors (Castner et…”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686 · cited 2×
“Furthermore, the expression of BDNF mRNA, which is tightly dependent on the activation of intra-synaptic NMDA receptors (Hardingham et al., 2002), reaches its maximum level in the PFC during late adolescence and young adulthood (Webster et al., 2002).”
BackgroundGlutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“Consequently, acute exposure to low doses of NMDA antagonists induces psychotic symptoms and cognitive dysfunctions in pubertal/postpubertal rather than prepubertal ages (Olney and Farber, 1995).”
BackgroundThe neuropathology of schizophrenia
Harrison, P. J. (1999) · Brain · doi:10.1093/brain/122.4.593 · Cited by 1,677
Room, R., Babor, T., & Rehm, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17870-2 · Cited by 1,625 · cited 2×
“A similar effect was observed in the hippocampus of ethanol-withdrawn rats treated with acamprosate as compared to control animals (Room et al., 2005).”
BackgroundResultStructural maturation of neural pathways in children and adolescents: in vivo study
Paus, T., Zijdenbos, A., Worsley, K., Collins, D. L., Blumenthal, J., Giedd, J. N., Rapoport, J. L., & Evans, A. C. (1999) · Science · doi:10.1126/science.283.5409.1908 · Cited by 1,322
Schizophrenia as a Disorder of Neurodevelopment
Lewis, D. A., & Levitt, P. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142754 · Cited by 1,163
McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056 · cited 2×
“…on metabotropic glutamate (e.g., mGluR5) and NMDA receptors may provide a better and safer therapeutic strategy for early stages schizophrenia as compared to risperidone (McGorry et al., 2002), olanzapine (McGlashan et al., 2006, McGlashan et al., 2003) or D-cycloserine (Buchanan et al., 2007).”
BackgroundNeurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Toga, A. W., Thompson, P. M., & Sowell, E. R. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.007 · Cited by 872 · cited 1×
“…1989, Zecevic and Rakic, 1991), while the myelination of axons projecting from the PFC is particularly intense during adolescence and young adulthood (Giedd et al., 1999, Gogtay et al., 2004, Jernigan et al., 1991, Paus et al., 1999, Sowell et al., 2003, Sowell et al., 1999, Toga et al., 2006).”
BackgroundSeeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869 · cited 1×
“…that first and second generation antipsychotic drugs exert anti-DA effects, mainly by targeting D2 over D1 receptors (Creese et al., 1976, Seeman and Lee, 1975), prolonged blockade of D2 receptors can also lead to decreased expression of PFC D1 receptors (Castner et al., 2000, Lidow et…”
BackgroundIndependent cellular processes for hippocampal memory consolidation and reconsolidation
Lee, J. L. C., Everitt, B. J., & Thomas, K. L. (2004) · Science · doi:10.1126/science.1095760 · Cited by 825 · cited 1×
“Both D1 and D2 DA receptors are co-expressed in single striatal neurons and their co-activation can lead to calcium release from internal stores (Aizman et al., 2000, Lee et al., 2004, So et al., 2005) and increase neuronal activity (Hopf et al., 2003).”
BackgroundZahrt, J., Taylor, J. R., Mathew, R. G., & Arnsten, A. F. T. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08528.1997 · Cited by 796 · cited 1×
“An excessive stimulation of D1 receptors lead to cognitive dysfunction (Arnsten and Goldman-Rakic, 1998, Cai and Arnsten, 1997, Zahrt et al., 1997) whereas insufficient recruitment of these receptors is associated with working memory deficits (Castner et al., 2000, Sawaguchi and Goldman-Rakic,…”
BackgroundNeuroleptics and the Natural Course of Schizophrenia
Wyatt, R. J. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.325 · Cited by 787 · cited 1×
“Advantages of Using Acamprosate-like Drugs in Prodromal Stages of Schizophrenia It has been proposed that anti-DA treatments during the early stages of first-episode psychoses may be effective to prevent cognitive and emotional decline in schizophrenia (Lieberman, 1999, Wyatt, 1991).”
BackgroundSynaptogenesis in the Prefrontal Cortex of Rhesus Monkeys
Bourgeois, J.-P., Goldman-Rakic, P. S., & Rakic, P. (1994) · Cerebral Cortex · doi:10.1093/cercor/4.1.78 · Cited by 687
DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling
Millar, J. K., Pickard, B. S., Mackie, S., James, R., Christie, S., Buchanan, S. R., Malloy, M. P., Chubb, J. E., Huston, E., Baillie, G. S., et al. (2005) · Science · doi:10.1126/science.1112915 · Cited by 648 · cited 1×
“More importantly, it was found that the PDE4B enzyme interacts with the disrupted in schizophrenia 1 (DISC 1) gene in a manner that PDE4B can be released from DISC 1 when the dendritic levels of cyclic adenosine monophosphate (cAMP) are elevated (Millar et al., 2005).”
BackgroundMetabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption
Spanagel, R., Pendyala, G., Abarca, C., Zghoul, T., Sanchis-Segura, C., Magnone, M. C., Lascorz, J., Depner, M., Holzberg, D., Soyka, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1163 · Cited by 594 · cited 3×
“Furthermore, the increased ethanol intake observed in the hyperglutamatergic mice (Spanagel et al., 2005) raises the intriguing possibility that similar exacerbated glutamatergic condition may be driving, at least in part, the increased prevalence of ethanol abuse and dependence observed in schizophrenia.”
BackgroundInfluentialMcGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556 · cited 1×
“…on metabotropic glutamate (e.g., mGluR5) and NMDA receptors may provide a better and safer therapeutic strategy for early stages schizophrenia as compared to risperidone (McGorry et al., 2002), olanzapine (McGlashan et al., 2006, McGlashan et al., 2003) or D-cycloserine (Buchanan et al., 2007).”
BackgroundSowell, E. R., Thompson, P. M., Holmes, C. J., Batth, R., Jernigan, T. L., & Toga, A. W. (1999) · NeuroImage · doi:10.1006/nimg.1999.0436 · Cited by 554 · cited 1×
“…1989, Zecevic and Rakic, 1991), while the myelination of axons projecting from the PFC is particularly intense during adolescence and young adulthood (Giedd et al., 1999, Gogtay et al., 2004, Jernigan et al., 1991, Paus et al., 1999, Sowell et al., 2003, Sowell et al., 1999, Toga et al., 2006).”
BackgroundGur, R. E., Cowell, P., Turetsky, B. I., Gallacher, F., Cannon, T., Bilker, W., & Gur, R. C. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.2.145 · Cited by 540 · cited 1×
“Thus, the lack of cognitive improvement could be due to the anatomical and cellular alterations induced by prolonged antipsychotic exposure as these changes seem to be positively correlated with the cumulative doses of antipsychotic exposure (Cahn et al., 2002, Gur et al., 1998).”
BackgroundKrystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530 · cited 2×
“According to this new paradigm, hyperactive glutamatergic neurons in several brain regions including the PFC may underlie the psychotic, cognitive and emotional manifestations in schizophrenia (Krystal et al., 2003, Moghaddam, 2003).”
BackgroundKellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520 · cited 1×
“Along with this hypothesis, transgenic mice overexpressing D2 receptors in the striatum exhibit severe deficits in working memory-dependent tasks in association with increased D1 receptor responses in the PFC (Kellendonk et al., 2006).”
BackgroundNMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467 · cited 1×
“…hippocampal GABAergic interneurons that control pyramidal neuron firing are particularly sensitive to psychotomimetic doses of NMDA antagonists (Grunze et al., 1996); 6) Neuroimaging studies indicating that psychotic symptoms and cognitive abnormalities elicited by acute administration of…”
BackgroundBarriers to Employment for People With Schizophrenia
Rosenheck, R., Leslie, D., Keefe, R., McEvoy, J., Swartz, M., Perkins, D., Stroup, S., Hsiao, J. K., Lieberman, J., & CATIE Study Investigators Group (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.411 · Cited by 465
MATURATION OF HUMAN CEREBRUM OBSERVED IN VIVO DURING ADOLESCENCE
JERNIGAN, T. L., TRAUNER, D. A., HESSELINK, J. R., & TALLAL, P. A. (1991) · Brain · doi:10.1093/brain/114.5.2037 · Cited by 444
Jackson, M. E., Homayoun, H., & Moghaddam, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308455101 · Cited by 430
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426 · cited 1×
“…are correlated with increased glutamate levels in the PFC (Adams and Moghaddam, 1998); 3) Pharmacological studies showing that glutamate release inhibitors such as lamotrigine (Anand et al., 2000) and mGluR 2 agonists (Moghaddam and Adams, 1998) ameliorate the cognitive Eur Neuropsychopharmacol.”
BackgroundBuchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419 · cited 3×
“Drugs with similar acamprosate-like profile on metabotropic glutamate (e.g., mGluR5) and NMDA receptors may provide a better and safer therapeutic strategy for early stages schizophrenia as compared to risperidone (McGorry et al., 2002), olanzapine (McGlashan et al., 2006, McGlashan et al., 2003) or D-cycloserine (Buc…”
BackgroundTseng, K. Y., & O'Donnell, P. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1021-04.2004 · Cited by 402 · cited 4×
“Because DA-dependent attenuation of PFC NMDA responses involves activation of local GABAergic interneurons (Tseng and O'Donnell, 2004), a reduction of this inhibitory tone may also contribute to trigger and sustain the hyperglutamatergic state in the PFC.”
BackgroundInfluentialSelf-citation(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.805 · Cited by 392 · cited 1×
“…and cognitive abnormalities elicited by acute administration of ketamine in healthy volunteers concur with an enhancement of PFC metabolic activity (Breier et al., 1997, Holcomb et al., 2005, Holcomb et al., 2001); 7) Proton magnetic resonance spectroscopy studies showing that glutamine levels, an…”
BackgroundAssociation and linkage analyses of RGS4 polymorphisms in schizophrenia
Chowdari, K. V. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.12.1373 · Cited by 368
Dopamine Modulation of Prefrontal Cortical Interneurons Changes during Adolescence
Tseng, K.-Y., & O'Donnell, P. (2006) · Cerebral Cortex · doi:10.1093/cercor/bhl034 · Cited by 339 · cited 5×
“A similar delayed acquisition of mature responses to DA has been recently observed in PFC interneurons (Tseng and O'Donnell, 2007a, Tseng and O'Donnell, 2007b).”
BackgroundInfluentialSelf-citationRowland, L. M., Bustillo, J. R., Mullins, P. G., Jung, R. E., Lenroot, R., Landgraf, E., Barrow, R., Yeo, R., Lauriello, J., & Brooks, W. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.394 · Cited by 304
Sun, X., Zhao, Y., & Wolf, M. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4603-04.2005 · Cited by 299 · cited 1×
“…activation increases surface expression of AMPA receptor subunits in cortical neurons through a PKA-dependent mechanism (Smith et al., 2005, Sun et al., 2005), and alter the strength of synaptic communication induced by longterm potentiation (LTP) (Malenka, 2003), a cellular mechanism for…”
BackgroundCai, J. X., & Arnsten, A. F. T. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36983-6 · Cited by 285 · cited 1×
“An excessive stimulation of D1 receptors lead to cognitive dysfunction (Arnsten and Goldman-Rakic, 1998, Cai and Arnsten, 1997, Zahrt et al., 1997) whereas insufficient recruitment of these receptors is associated with working memory deficits (Castner et al., 2000, Sawaguchi and Goldman-Rakic,…”
BackgroundChanges in synaptic density in motor cortex of rhesus monkey during fetal and postnatal life
Zecevic, N., Bourgeois, J.-P., & Rakic, P. (1989) · Developmental Brain Research · doi:10.1016/0165-3806(89)90124-7 · Cited by 253 · cited 1×
“…connections in the PFC occurs during this developmental stage (Bourgeois et al., 1994, Huttenlocher, 1979, Huttenlocher and Dabholkar, 1997, Zecevic et al., 1989, Zecevic and Rakic, 1991), while the myelination of axons projecting from the PFC is particularly intense during adolescence and…”
BackgroundSmith, W. B., Starck, S. R., Roberts, R. W., & Schuman, E. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.015 · Cited by 252 · cited 1×
“Indeed, D1 receptor activation increases surface expression of AMPA receptor subunits in cortical neurons through a PKA-dependent mechanism (Smith et al., 2005, Sun et al., 2005), and alter the strength of synaptic communication induced by longterm potentiation (LTP) (Malenka, 2003), a cellular…”
BackgroundChildhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225 · cited 1×
“However, none of these so-called second-generation antipsychotics have achieved similar efficacy to clozapine (Azorin et al., 2001, Breier et al., 1999, Chakos et al., 2001, Conley et al., 1999, Davis et al., 2003, McEvoy et al., 2006, Shaw et al., 2006).”
BackgroundNeuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201 · cited 3×
“…glutamatergic transmission and glutamate release (De Witte, 2004, Krystal et al., 2003), the increased glutamate would reach the extrasynaptic space, which in turn would stimulate more mGluR5 receptors and cause even more glutamate release and abnormal NMDA activation (De Witte et al., 2005).”
BackgroundInfluentialThe expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia
Benes, F. M., Matzilevich, D., Burke, R. E., & Walsh, J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001758 · Cited by 183 · cited 1×
“However, neuropathological and gene expression studies aimed to support the existence of first psychosis-induced neurotoxicity have yielded negative results (Benes et al., 2006, Benes et al., 2003, Damadzic et al., 2001, Harrison, 1999).”
O'Donnell, P. (2002) · Cerebral Cortex · doi:10.1093/cercor/12.9.975 · Cited by 172 · cited 1×
“The characteristic post-pubertal emergence of PFC glutamatergic hyperactivity (O'Donnell et al., 2002, Tseng et al., 2007) and hyperreactive PFC metabolic response to mesocortical stimulation (Tseng et al., 2006a) are correlated with a selective down regulation of PFC glutamate decarboxylase-67…”
BackgroundPost-pubertal Emergence of Prefrontal Cortical Up States Induced by D1-NMDA Co-activation
Tseng, K. Y. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh107 · Cited by 169 · cited 4×
“Electrophysiological recordings of PFC pyramidal neurons at different maturational stages have revealed that DA-glutamate interactions in the PFC mature after puberty (Tseng and O'Donnell, 2004, Tseng and O'Donnell, 2005).”
BackgroundInfluentialSelf-citationTarazi, F. I., Tomasini, E. C., & Baldessarini, R. (1999) · Developmental Neuroscience · doi:10.1159/000017365 · Cited by 169
Tauscher, J., Hussain, T., Agid, O., Verhoeff, N. P. L. G., Wilson, A. A., Houle, S., Remington, G., Zipursky, R. B., & Kapur, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1620 · Cited by 159 · cited 2×
“In this regard, it is appealing that clozapine binds D1 receptors with a higher affinity than D2 receptors (Chou et al., 2006, Tauscher et al., 2004).”
BackgroundTseng, K. Y., & O'Donnell, P. (2007) · Synapse · doi:10.1002/syn.20432 · Cited by 141
Self-citationSmith, K. E., Gibson, E. S., & Dell’Acqua, M. L. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3092-05.2006 · Cited by 141 · cited 1×
“…levels (Eastwood et al., 2005, Gerber et al., 2003), a phosphatase that normally reduces the excitability of NMDA receptors (Rycroft and Gibb, 2004, Smith et al., 2006), may also enhance NMDA function and promote working memory deficits in response to low doses of the NMDA antagonist MK801…”
BackgroundRegional alterations in RGS4 protein in schizophrenia
Erdely, H. A., Tamminga, C. A., Roberts, R. C., & Vogel, M. W. (2006) · Synapse · doi:10.1002/syn.20265 · Cited by 99 · cited 1×
“Furthermore, a reduced expression of the RSG4 gene (Chowdari et al., 2002, Erdely et al., 2006, Prasad et al., 2005, Saugstad et al., 1998), which encodes a protein product that normally decreases the activation of mGluR5, may result in over-activation of NMDA receptors.”
BackgroundArnsten, A. F. T., & Goldman-Rakic, P. S. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.4.362 · Cited by 6 · cited 1×
“An excessive stimulation of D1 receptors lead to cognitive dysfunction (Arnsten and Goldman-Rakic, 1998, Cai and Arnsten, 1997, Zahrt et al., 1997) whereas insufficient recruitment of these receptors is associated with working memory deficits (Castner et al., 2000, Sawaguchi and Goldman-Rakic,…”
Background
Cited by
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
“while co-agonists of theNMDA receptors, such asD-serine and glycine, improve cognition andnegative symptoms in schizophrenia [360,361].”
BackgroundBussey, T. J., Holmes, A., Lyon, L., Mar, A. C., McAllister, K. A. L., Nithianantharajah, J., Oomen, C. A., & Saksida, L. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.011 · Cited by 299
Fast synaptic subcortical control of hippocampal circuits
Varga, V., Losonczy, A., Zemelman, B. V., Borhegyi, Z., Nyiri, G., Domonkos, A., Hangya, B., Holderith, N., Magee, J. C., & Freund, T. F. (2009) · Science · doi:10.1126/science.1178307 · Cited by 248
Kinon, B. J., Millen, B. A., Zhang, L., & McKinzie, D. L. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.016 · Cited by 169
Metadata
- Authors
- Paz, R. D., Tardito, S., Atzori, M., & Tseng, K. Y.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 18
- Issue
- 11
- Pages
- 773-786
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2046327370
- Cited by
- 141
- References
- 66
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.